ArticleClinical rheumatology2025
Glucagon-like peptide-1 receptor analog use is associated with reduced thromboembolic events compared with dipeptidyl peptidase-4 inhibitors in rheumatoid arthritis patients: A global retrospective cohort study.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation.European heart journal. Cardiovascular pharmacotherapy · 2026Article
- Glucagon-like Peptide-1 Receptor Agonists in Rheumatoid Arthritis: A Scoping Review of Metabolic, Anti-Inflammatory, and Cardioprotective Effects.Journal of personalized medicine · 2026Review
- Cardioprotective mechanisms and effects of glucagon-like peptide-1 receptor agonists in autoimmune rheumatic diseases.Rheumatology (Oxford, England) · 2026Review
- GLP-1 Receptor Agonists and Cardiovascular Events in Adults with Obesity and Autoimmune Disease: A Target Trial Emulation.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRheumatoid arthritis (RA) is an inflammatory disease associated with thromboembolic events. Glucagon-like peptide-1 (GLP-1) analogs, which are used in type 2 diabetes mellitus (T2DM), have shown potential anti-inflammatory effects, but their role in thrombotic events in RA is less clear. This study compares GLP-1 analogs to dipeptidyl peptidase 4 inhibitors (DPP4i) regarding thromboembolic events in RA.
methodsWe performed a retrospective cohort study using TriNetX database to evaluate adult patients who carried the diagnosis of RA from January 1, 2006 to December 1, 2024 with co-existing T2DM and who initiated GLP-1 analogs or DPP4i after diagnosis of RA and T2DM. Patients were divided into two cohorts (GLP-1 vs. DPP4i), and the primary outcome was all thromboembolic events (cerebral infarction, myocardial infarction [MI], deep vein thrombosis [DVT], pulmonary embolism [PE]) within 5 years after GLP-1 analog or DPP4i start. Secondary outcomes included individual events, arterial and venous thrombosis, and all-cause mortality. Propensity score matching adjusted for demographic, clinical, and treatment variables.
resultsWe analyzed 41,153 patients, including 25,425 GLP-1 analog and 15,728 DPP4i users, and compared 8,697 matched patients in each group. The median age at medication start was 65 years old, with 70% females. GLP-1 analog users had a 24% lower risk of all thrombotic events (hazard ratio [HR], 0.76 [95% CI: 0.70, 0.83]; p < 0.0001), as well as reduced risks of individual events and an overall lower mortality.
conclusionCompared to DPP4i, GLP-1 analogs may lower the risk of thromboembolic events and reduce all-cause mortality in RA patients with T2DM. Key Points • The study identified significantly reduced risks in both arterial and venous thrombosis in RA patients receiving GLP-1 analogs compared with DPP4i. • RA patients who received GLP-1 analogs had lower all-cause mortality compared to those receiving DPP4i. • These findings support potential dual benefit of GLP-1 analogs in reducing inflammation and thrombosis in RA patients with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.